Economic comparisons of the pharmacotherapy of depression: an overview
Identifieur interne : 001F19 ( Istex/Corpus ); précédent : 001F18; suivant : 001F20Economic comparisons of the pharmacotherapy of depression: an overview
Auteurs : R. Crott ; P. GilisSource :
- Acta Psychiatrica Scandinavica [ 0001-690X ] ; 1998-04.
English descriptors
- KwdEn :
Abstract
As many countries find that their health care expenditure is taking up an increasing proportion of their financial resources, economic aspects of care processes have become more important in the choice of optimal strategies. This review of the economic studies of the comparative treatment of depression shows that nearly every aspect of treatment has important economic consequences. Cost‐of‐illness studies have documented the high burden on society of this disorder, and the associated loss of productivity and work. Comparative cost‐effectiveness/utility studies, the majority of which are based on modelling techniques, have consistently shown a better cost‐effectiveness ratio of the newer antidepressants over more traditional tricyclic antidepressants (TCAs), when all therapy‐related costs are taken into account.
Url:
DOI: 10.1111/j.1600-0447.1998.tb09995.x
Links to Exploration step
ISTEX:012ACD1C71D7DE54000254AC9B500D3543F595B8Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Economic comparisons of the pharmacotherapy of depression: an overview</title><author><name sortKey="Crott, R" sort="Crott, R" uniqKey="Crott R" first="R." last="Crott">R. Crott</name><affiliation><mods:affiliation>Faculty of Pharmacy, University of Montreal, Montreal, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>R. Crott, Faculté de Pharmacie, Université de Montreal, succursale Centre‐Ville, Pavilion Principal CP 6128, Montreal, Canada</mods:affiliation></affiliation></author><author><name sortKey="Gilis, P" sort="Gilis, P" uniqKey="Gilis P" first="P." last="Gilis">P. Gilis</name><affiliation><mods:affiliation>Eli Lilly Benelux, Brussels, Belgium</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:012ACD1C71D7DE54000254AC9B500D3543F595B8</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1111/j.1600-0447.1998.tb09995.x</idno><idno type="url">https://api-v5.istex.fr/document/012ACD1C71D7DE54000254AC9B500D3543F595B8/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001F19</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001F19</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Economic comparisons of the pharmacotherapy of depression: an overview</title><author><name sortKey="Crott, R" sort="Crott, R" uniqKey="Crott R" first="R." last="Crott">R. Crott</name><affiliation><mods:affiliation>Faculty of Pharmacy, University of Montreal, Montreal, Canada</mods:affiliation></affiliation><affiliation><mods:affiliation>R. Crott, Faculté de Pharmacie, Université de Montreal, succursale Centre‐Ville, Pavilion Principal CP 6128, Montreal, Canada</mods:affiliation></affiliation></author><author><name sortKey="Gilis, P" sort="Gilis, P" uniqKey="Gilis P" first="P." last="Gilis">P. Gilis</name><affiliation><mods:affiliation>Eli Lilly Benelux, Brussels, Belgium</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Psychiatrica Scandinavica</title><idno type="ISSN">0001-690X</idno><idno type="eISSN">1600-0447</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1998-04">1998-04</date><biblScope unit="volume">97</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="241">241</biblScope><biblScope unit="page" to="252">252</biblScope></imprint><idno type="ISSN">0001-690X</idno></series><idno type="istex">012ACD1C71D7DE54000254AC9B500D3543F595B8</idno><idno type="DOI">10.1111/j.1600-0447.1998.tb09995.x</idno><idno type="ArticleID">ACPS241</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-690X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>cost‐effectiveness</term><term>depression</term><term>selective serotonin reuptake inhibitors</term><term>tricyclic antidepressants</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">As many countries find that their health care expenditure is taking up an increasing proportion of their financial resources, economic aspects of care processes have become more important in the choice of optimal strategies. This review of the economic studies of the comparative treatment of depression shows that nearly every aspect of treatment has important economic consequences. Cost‐of‐illness studies have documented the high burden on society of this disorder, and the associated loss of productivity and work. Comparative cost‐effectiveness/utility studies, the majority of which are based on modelling techniques, have consistently shown a better cost‐effectiveness ratio of the newer antidepressants over more traditional tricyclic antidepressants (TCAs), when all therapy‐related costs are taken into account.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>R. Crott</name><affiliations><json:string>Faculty of Pharmacy, University of Montreal, Montreal, Canada</json:string><json:string>R. Crott, Faculté de Pharmacie, Université de Montreal, succursale Centre‐Ville, Pavilion Principal CP 6128, Montreal, Canada</json:string></affiliations></json:item><json:item><name>P. Gilis</name><affiliations><json:string>Eli Lilly Benelux, Brussels, Belgium</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>depression</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>tricyclic antidepressants</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>selective serotonin reuptake inhibitors</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cost‐effectiveness</value></json:item></subject><articleId><json:string>ACPS241</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><abstract>As many countries find that their health care expenditure is taking up an increasing proportion of their financial resources, economic aspects of care processes have become more important in the choice of optimal strategies. This review of the economic studies of the comparative treatment of depression shows that nearly every aspect of treatment has important economic consequences. Cost‐of‐illness studies have documented the high burden on society of this disorder, and the associated loss of productivity and work. Comparative cost‐effectiveness/utility studies, the majority of which are based on modelling techniques, have consistently shown a better cost‐effectiveness ratio of the newer antidepressants over more traditional tricyclic antidepressants (TCAs), when all therapy‐related costs are taken into account.</abstract><qualityIndicators><score>6.868</score><pdfVersion>1.4</pdfVersion><pdfPageSize>597.6 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>822</abstractCharCount><pdfWordCount>7879</pdfWordCount><pdfCharCount>52081</pdfCharCount><pdfPageCount>12</pdfPageCount><abstractWordCount>114</abstractWordCount></qualityIndicators><title>Economic comparisons of the pharmacotherapy of depression: an overview</title><genre><json:string>review-article</json:string></genre><host><title>Acta Psychiatrica Scandinavica</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1600-0447</json:string></doi><issn><json:string>0001-690X</json:string></issn><eissn><json:string>1600-0447</json:string></eissn><publisherId><json:string>ACPS</json:string></publisherId><volume>97</volume><issue>4</issue><pages><first>241</first><last>252</last><total>12</total></pages><genre><json:string>journal</json:string></genre></host><categories><wos><json:string>social science</json:string><json:string>psychiatry</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>psychiatry</json:string></scienceMetrix><inist><json:string>sciences humaines et sociales</json:string></inist></categories><publicationDate>1998</publicationDate><copyrightDate>1998</copyrightDate><doi><json:string>10.1111/j.1600-0447.1998.tb09995.x</json:string></doi><id>012ACD1C71D7DE54000254AC9B500D3543F595B8</id><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api-v5.istex.fr/document/012ACD1C71D7DE54000254AC9B500D3543F595B8/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api-v5.istex.fr/document/012ACD1C71D7DE54000254AC9B500D3543F595B8/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api-v5.istex.fr/document/012ACD1C71D7DE54000254AC9B500D3543F595B8/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Economic comparisons of the pharmacotherapy of depression: an overview</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>1998</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Economic comparisons of the pharmacotherapy of depression: an overview</title><author xml:id="author-1"><persName><forename type="first">R.</forename><surname>Crott</surname></persName><affiliation>Faculty of Pharmacy, University of Montreal, Montreal, Canada</affiliation><affiliation>R. Crott, Faculté de Pharmacie, Université de Montreal, succursale Centre‐Ville, Pavilion Principal CP 6128, Montreal, Canada</affiliation></author><author xml:id="author-2"><persName><forename type="first">P.</forename><surname>Gilis</surname></persName><affiliation>Eli Lilly Benelux, Brussels, Belgium</affiliation></author></analytic><monogr><title level="j">Acta Psychiatrica Scandinavica</title><idno type="pISSN">0001-690X</idno><idno type="eISSN">1600-0447</idno><idno type="DOI">10.1111/(ISSN)1600-0447</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1998-04"></date><biblScope unit="volume">97</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="241">241</biblScope><biblScope unit="page" to="252">252</biblScope></imprint></monogr><idno type="istex">012ACD1C71D7DE54000254AC9B500D3543F595B8</idno><idno type="DOI">10.1111/j.1600-0447.1998.tb09995.x</idno><idno type="ArticleID">ACPS241</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1998</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>As many countries find that their health care expenditure is taking up an increasing proportion of their financial resources, economic aspects of care processes have become more important in the choice of optimal strategies. This review of the economic studies of the comparative treatment of depression shows that nearly every aspect of treatment has important economic consequences. Cost‐of‐illness studies have documented the high burden on society of this disorder, and the associated loss of productivity and work. Comparative cost‐effectiveness/utility studies, the majority of which are based on modelling techniques, have consistently shown a better cost‐effectiveness ratio of the newer antidepressants over more traditional tricyclic antidepressants (TCAs), when all therapy‐related costs are taken into account.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>depression</term></item><item><term>tricyclic antidepressants</term></item><item><term>selective serotonin reuptake inhibitors</term></item><item><term>cost‐effectiveness</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1998-04">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api-v5.istex.fr/document/012ACD1C71D7DE54000254AC9B500D3543F595B8/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1600-0447</doi><issn type="print">0001-690X</issn><issn type="electronic">1600-0447</issn><idGroup><id type="product" value="ACPS"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="ACTA PSYCHIATRICA SCANDINAVICA">Acta Psychiatrica Scandinavica</title></titleGroup></publicationMeta><publicationMeta level="part" position="04004"><doi origin="wiley">10.1111/acp.1998.97.issue-4</doi><numberingGroup><numbering type="journalVolume" number="97">97</numbering><numbering type="journalIssue" number="4">4</numbering></numberingGroup><coverDate startDate="1998-04">April 1998</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="0024100" status="forIssue"><doi origin="wiley">10.1111/j.1600-0447.1998.tb09995.x</doi><idGroup><id type="unit" value="ACPS241"></id></idGroup><countGroup><count type="pageTotal" number="12"></count></countGroup><titleGroup><title type="tocHeading1">Review article</title></titleGroup><eventGroup><event type="firstOnline" date="2007-11-13"></event><event type="publishedOnlineFinalForm" date="2007-11-13"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-10"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-01"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="241">241</numbering><numbering type="pageLast" number="252">252</numbering></numberingGroup><correspondenceTo>R. Crott, Faculté de Pharmacie, Université de Montreal, succursale Centre‐Ville, Pavilion Principal CP 6128, Montreal, Canada</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ACPS.ACPS241.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Accepted for publication August 16, 1997</unparsedEditorialHistory><countGroup><count type="referenceTotal" number="91"></count><count type="linksCrossRef" number="3"></count></countGroup><titleGroup><title type="main">Economic comparisons of the pharmacotherapy of depression: an overview</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1" corresponding="yes"><personName><givenNames>R.</givenNames><familyName>Crott</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>P.</givenNames><familyName>Gilis</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="CA"><unparsedAffiliation>Faculty of Pharmacy, University of Montreal, Montreal, Canada</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="BE"><unparsedAffiliation>Eli Lilly Benelux, Brussels, Belgium</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">depression</keyword><keyword xml:id="k2">tricyclic antidepressants</keyword><keyword xml:id="k3">selective serotonin reuptake inhibitors</keyword><keyword xml:id="k4">cost‐effectiveness</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p>As many countries find that their health care expenditure is taking up an increasing proportion of their financial resources, economic aspects of care processes have become more important in the choice of optimal strategies. This review of the economic studies of the comparative treatment of depression shows that nearly every aspect of treatment has important economic consequences. Cost‐of‐illness studies have documented the high burden on society of this disorder, and the associated loss of productivity and work. Comparative cost‐effectiveness/utility studies, the majority of which are based on modelling techniques, have consistently shown a better cost‐effectiveness ratio of the newer antidepressants over more traditional tricyclic antidepressants (TCAs), when all therapy‐related costs are taken into account.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Economic comparisons of the pharmacotherapy of depression: an overview</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Economic comparisons of the pharmacotherapy of depression: an overview</title></titleInfo><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Crott</namePart><affiliation>Faculty of Pharmacy, University of Montreal, Montreal, Canada</affiliation><affiliation>R. Crott, Faculté de Pharmacie, Université de Montreal, succursale Centre‐Ville, Pavilion Principal CP 6128, Montreal, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Gilis</namePart><affiliation>Eli Lilly Benelux, Brussels, Belgium</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">1998-04</dateIssued><edition>Accepted for publication August 16, 1997</edition><copyrightDate encoding="w3cdtf">1998</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">91</extent></physicalDescription><abstract lang="en">As many countries find that their health care expenditure is taking up an increasing proportion of their financial resources, economic aspects of care processes have become more important in the choice of optimal strategies. This review of the economic studies of the comparative treatment of depression shows that nearly every aspect of treatment has important economic consequences. Cost‐of‐illness studies have documented the high burden on society of this disorder, and the associated loss of productivity and work. Comparative cost‐effectiveness/utility studies, the majority of which are based on modelling techniques, have consistently shown a better cost‐effectiveness ratio of the newer antidepressants over more traditional tricyclic antidepressants (TCAs), when all therapy‐related costs are taken into account.</abstract><subject lang="en"><genre>keywords</genre><topic>depression</topic><topic>tricyclic antidepressants</topic><topic>selective serotonin reuptake inhibitors</topic><topic>cost‐effectiveness</topic></subject><relatedItem type="host"><titleInfo><title>Acta Psychiatrica Scandinavica</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0001-690X</identifier><identifier type="eISSN">1600-0447</identifier><identifier type="DOI">10.1111/(ISSN)1600-0447</identifier><identifier type="PublisherID">ACPS</identifier><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>97</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>241</start><end>252</end><total>12</total></extent></part></relatedItem><identifier type="istex">012ACD1C71D7DE54000254AC9B500D3543F595B8</identifier><identifier type="DOI">10.1111/j.1600-0447.1998.tb09995.x</identifier><identifier type="ArticleID">ACPS241</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F19 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001F19 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:012ACD1C71D7DE54000254AC9B500D3543F595B8
|texte= Economic comparisons of the pharmacotherapy of depression: an overview
}}
| This area was generated with Dilib version V0.6.29. |  |